603566.SH
普莱柯
SSE · Healthcare · Biotechnology · CN
CNY 10.22
−0.68%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 1.1B | 1.0B | 1.3B | 1.2B |
| Cost of Revenue | 437.5M | 437.4M | 405.6M | 488.4M | 459.7M |
| Gross Profit | 623.0M | 652.5M | 636.9M | 764.3M | 770.3M |
| Operating Expenses | |||||
| R&D Expense | 98.8M | 99.7M | 106.0M | 101.1M | 92.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 108.5M | 105.6M | 118.2M | 98.0M | 106.6M |
| Selling & Marketing Expense | 243.3M | 256.0M | 295.4M | 352.0M | 367.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 467.7M | 477.7M | 534.2M | 562.5M | 575.2M |
| Cost and Expenses | 905.2M | 915.0M | 939.9M | 1.1B | 1.0B |
| Operating Income (EBIT) | 189.6M | 206.5M | 97.8M | 193.0M | 176.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 190.2M | 207.3M | 98.8M | 194.6M | 177.7M |
| Income Tax Expense | 22.4M | 22.3M | 6.0M | 20.1M | 9.9M |
| Bottom Line | |||||
| Net Income | 172.8M | 185.0M | 92.8M | 174.5M | 167.8M |
| Earnings from Cont. Ops | 167.7M | 185.0M | 92.8M | 174.5M | 167.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 172.8M | 185.0M | 92.8M | 174.5M | 167.8M |
| Per Share | |||||
| Basic EPS | CN¥0.51 | CN¥0.54 | CN¥0.27 | CN¥0.50 | CN¥0.52 |
| Diluted EPS | CN¥0.51 | CN¥0.54 | CN¥0.27 | CN¥0.50 | CN¥0.52 |
| Revenue Per Share | CN¥3.12 | CN¥3.18 | CN¥3.03 | CN¥3.59 | CN¥3.81 |
| Shares | |||||
| Basic Shares Outstanding | 339.5M | 342.6M | 343.7M | 349.0M | 322.7M |
| Diluted Shares Outstanding | 339.5M | 342.6M | 343.7M | 349.0M | 322.7M |
| Profitability Metrics | |||||
| EBITDA | — | 328.7M | 219.2M | 285.4M | 251.3M |
| D&A | — | 122.2M | 121.4M | 92.3M | 74.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026